RxDoctor Payments Data

Richard Duff, MD

Pulmonary Disease · Myrtle Beach, SCNPI 1447392444

Payments from drug & device makers

$3,153in general payments, 2019–2025

Across 60 payments — averaging $52.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • GSK$344
  • TELA Bio, Inc.$173
  • Inari Medical, Inc.$146
  • Stryker$142
  • Insmed, Inc.$126
  • plus $585 from 19 others

What the payments were for

  • Travel & lodging$1,54049%
  • Food & beverage$1,48347%
  • Education$1304%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,153 in reported general payments places this provider in the 45th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$82,886
Medicare patients
253
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$16,303
Breo ElliptaFluticasone/Vilanterol25$12,463
EliquisApixaban20$7,333
Wixela InhubFluticasone Propion/Salmeterol14$1,213
SynthroidLevothyroxine Sodium11$544
Montelukast Sodium25$468
Duloxetine Hcl19$430
Albuterol Sulfate HfaAlbuterol Sulfate11$331
Omeprazole32$327
Baclofen13$285
Levothyroxine Sodium24$242
Memantine Hcl16$240
Tamsulosin Hcl18$237
Furosemide23$209
ClopidogrelClopidogrel Bisulfate20$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$344$28,76637 claims
PfizerEliquis$24$7,33320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →